Targeting of CD34 + CD38 - cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
Pre-publication versions of this article are available by contacting email@example.com.
|24 Apr 2012||Submitted||Original manuscript|
|15 Jun 2012||Reviewed||Reviewer Report - Judith Karp|
|30 Jun 2012||Reviewed||Reviewer Report - Jörg Cammenga|
|25 Jul 2012||Author responded||Author comments - claire SEEDHOUSE|
|Resubmission - Version 2|
|25 Jul 2012||Submitted||Manuscript version 2|
|9 Sep 2012||Reviewed||Reviewer Report - Judith Karp|
|19 Sep 2012||Reviewed||Reviewer Report - Jörg Cammenga|
|Resubmission - Version 3|
|Submitted||Manuscript version 3|
|21 Sep 2012||Editorially accepted|
|26 Sep 2012||Article published||10.1186/1471-2407-12-431|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.